We are tempted to speculate that patients with cancer with higher FVIIa-AT levels, marking increased TF mRNA levels, may have the greater benefit of TF-tailored therapies, from FXa inhibitors to TF-directed antibody–drug conjugates. Here, F10 is linked to cancer.